$CRY (CryoLife Inc.)

$CRY {{ '2016-04-14T15:34:11+0000' | timeago}} • Announcement

$CRY said it has exercised its right to acquire the PhotoFix bovine pericardium patch from Genesee BioMedical for $2.3MM in cash. $CRY acquired the distribution rights and purchase option for PhotoFix in Aug. 2014. This includes about $0.6MM that $CRY previously provided to Genesee as advance under distribution agreement.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$LIVN {{ '2018-01-11T17:37:05+0000' | timeago}} • Announcement

$LIVN said the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant Study. The study is expected to enroll about 230 patients at 15 sites from the U.S. and Canada to ascertain whether valve leaflets are fully operational following surgery.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$BSX {{ '2018-01-09T20:36:17+0000' | timeago}} • Announcement

Healthcare solutions firm $BSX said its 4Q17 sales is estimated to have grown about 8% YoY, on a reported basis, to $2.41Bil. In the whole of fiscal 2017, sales advanced 8% annually to $9.05Bil. The growth reflects strong sales performance by all product groups.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$LIVN {{ '2018-01-08T14:58:25+0000' | timeago}} • Announcement

$LIVN announced Matthew J. Dodds has joined the company as SVP, Corporate Development. In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications.

$BAX {{ '2018-01-08T14:03:11+0000' | timeago}} • Announcement

$BAX will acquire two products from Mallinckrodt plc, RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant, for an upfront payment of approx. $153MM and potential contingent payments in future. The deal is expected to be modestly accretive to 2018 adjusted earnings and increasingly accretive thereafter and is expected to close in 1H18.

$IART {{ '2018-01-08T12:15:32+0000' | timeago}} • Announcement

$IART said it expects 4Q17 revenue to be approx $365MM, an increase of over 40% compared to 4Q16, helped by Derma Sciences and Codman Neurosurgery acquisitions. The results will be announced in late February, 2018.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$TFX {{ '2018-01-02T14:56:01+0000' | timeago}} • Announcement

$TFX completed its senior leadership transition. Effective Jan. 1, 2018, Liam Kelly, who was previously President & COO, assumed the position of President & CEO. Mr. Kelly succeeds Benson Smith, who retired as CEO, effective Dec. 31, 2017. Mr. Smith will continue to serve as non-executive Chairman of the Board.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

$PFE {{ '2017-12-18T19:31:58+0000' | timeago}} • Announcement

The BoD of $PFE has increased the quarterly dividend by 6% to $0.34 per share. The first quarter 2018 cash dividend will be payable on March 1, 2018, to shareholders of record on Feb. 2, 2018. The board also authorized a new $10Bil share repurchase program, in addition to the $6.4Bil remaining under the current authorization.

$ABT {{ '2017-12-15T16:46:17+0000' | timeago}} • Announcement

$ABT increased the company's quarterly common dividend to $0.28 per share from $0.265 per share.  The cash dividend is payable Feb. 15, 2018, to shareholders of record at the close of business on Jan. 12, 2018.

$TFX {{ '2017-12-12T15:30:39+0000' | timeago}} • Announcement

$TFX's respiratory division has signed a new group purchasing agreement with HealthTrust. The Respiratory Heaters & Accessories agreement which became effective Dec. 1, 2017, covers Teleflex's full line of Active Humidification, Non Invasive Ventilation (NIV), and High Flow Nasal Cannula Therapy (HFNCT) products.

Recent Transcripts

CMD (Cantel Medical Corp.)
Thursday, December 7 2017 - 4:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
ELGX (Endologix Inc.)
Tuesday, November 7 2017 - 9:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
BSX (Boston Scientific Corporation)
Thursday, October 26 2017 - 12:00pm
MMSI (Merit Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
BAX (Baxter International Inc.)
Wednesday, October 25 2017 - 12:30pm

AlphaGraphics you may like